U.S. markets open in 50 minutes

  • S&P Futures

    3,948.00
    +1.00 (+0.03%)
     

  • Dow Futures

    32,087.00
    +16.00 (+0.05%)
     

  • Nasdaq Futures

    12,643.50
    -1.25 (-0.01%)
     

  • Russell 2000 Futures

    1,747.20
    +8.80 (+0.51%)
     

  • Crude Oil

    66.06
    -0.68 (-1.02%)
     

  • Gold

    1,989.70
    +16.20 (+0.82%)
     

  • Silver

    22.59
    +0.13 (+0.59%)
     

  • EUR/USD

    1.0719
    +0.0048 (+0.45%)
     

  • 10-Yr Bond

    3.4210
    +0.0260 (+0.77%)
     

  • Vix

    26.44
    +3.45 (+15.01%)
     

  • GBP/USD

    1.2240
    +0.0066 (+0.54%)
     

  • USD/JPY

    131.3900
    -0.4130 (-0.31%)
     

  • Bitcoin USD

    28,335.86
    +1,022.28 (+3.74%)
     

  • CMC Crypto 200

    615.70
    +43.69 (+7.64%)
     

  • FTSE 100

    7,367.74
    +32.34 (+0.44%)
     

  • Nikkei 225

    26,945.67
    -388.12 (-1.42%)
     

GenKOre Announces Collaboration with a US-based Company on In vivo Gene-editing Therapy

CNW Group
·2 min read

SEOUL, South Korea, Jan. 25, 2023 /CNW/ -- GenKOre, Inc., a Korea-based biotech company with hypercompact CRISPR-Cas tools, announced that it has entered into a strategic research collaboration with a US-based biopharma company for the development of in vivo gene editing therapies. This collaboration will utilize GenKOre's proprietary CRISPR-Cas platform, TaRGET (Tiny nuclease, augment RNA-based Genome Editing Technology). The TaRGET platform is distinct from the most popular genome editing technology, CRISPR-Cas9, in that the whole editing module can be delivered with a single AAV vector. Based on their TaRGET platform, GenKOre has developed different modalities of editing tools including TaRGET-CUT, TaRGET-Adenine Base Editing (ABE), TaRGET-AI (Gene Activation and Inhibition system). and TaRGET-FREE (Gene knock-in) .

"This collaboration reflects the strength and potential utility of TaRGET platform in the application of in vivo gene-editing therapy", said Yong-Sam Kim, CEO of GenKOre. "Not only will this collaboration provide an opportunity to validate the applicability of TaRGET platform to in vivo therapy, but we will also expand the utility of our technologies to a wider spectrum of rare diseases." The collaboration was built on the mutual interest in forging transformative therapeutics for patients with rare diseases.

Under the terms of the agreement, GenKOre will receive up to 300 million USD including an upfront, option exercise fees and milestone payments upon successful achievement of R&D and commercial milestones across two in vivo disease targets. In addition, GenKOre will receive research funding and tiered royalties up to a double-digit percentage of net sales.

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/genkore-announces-collaboration-with-a-us-based-company-on-in-vivo-gene-editing-therapy-301725677.html

SOURCE GenKOre

Cision
Cision

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/January2023/25/c6606.html

Recommended Stories

  • Morgan Stanley Strategist Says Bank Stress Signals Bear Market End

    (Bloomberg) -- Morgan Stanley’s Michael Wilson said the stress in the banking system marks what’s likely to be the beginning of a painful and “vicious” end to the bear market in US stocks.Most Read from BloombergUBS to Buy Credit Suisse in $3.3 Billion Deal to End CrisisCredit Suisse’s $17 Billion of Risky Bonds Are Now WorthlessThe One Big Winner and Many Losers of UBS’s Credit Suisse RescueWarren Buffett in Contact With Biden Team on Banking CrisisCredit Suisse Said to Push Back Against UBS’s

  • How a 44-year-old built up enough ‘f–k you money’ to retire early: ‘It’s not just avoid avocado toast’

    Charmagne Chi joined the FIRE movement two years ago to pursue her passions. Her advice: Question every financial decision.

  • Analysts Warn Investors To Dump 10 Big Stocks Before It's Too Late

    Analysts don't usually tell investors to sell S&P 500 stocks. So when they do, it's wise to pay attention.

  • New York Community Bank shares surge and Foot Locker’s stock gains, but First Republic’s stock hit by S&P downgrade

    Here are some of the biggest movers on Monday with banks again in focus, after Swiss authorities forced the takeover of Swiss bank Credit Suisse by its peer UBS. New York Community Bancorp Inc. seems to have got a good deal in buying the assets of failed Signature Bank if the former’s share price reaction is anything to go by. NYCB stock (NYCB) was up 30% in premarket trading after the regional bank said it had acquired about $38 billion in Signature’s assets and was taking over all of its branches, prompting Wedbush to upgrade the stock to outperform from neutral.

  • Credit Suisse says $17 billion of its debt now worthless, angering bondholders

    Credit Suisse said 16 billion Swiss francs ($17.24 billion) of its Additional Tier 1 debt will be written down to zero on the orders of the Swiss regulator as part of its rescue merger with UBS, angering bondholders on Sunday. FINMA, the Swiss regulator, said the decision would bolster the bank's capital. The move reflects authorities' desire to see private investors share the pain from Credit Suisse's troubles.

  • Close to 190 banks could face Silicon Valley Bank's fate, according to a new study

    The Fed's aggressive interest rate hikes have eroded the value of bank assets such as government bonds and mortgage-backed securities.

  • This Bank Is Buying Signature Bank Assets. Its Stock Is Soaring.

    Much of what was once Signature Bank of New York is being acquired by a subsidiary of New York Community Bancorp, the Federal Deposit Insurance Corp. said Sunday, one week after the bank was shut down by regulators. New York Community Bancorp stock is soaring. Starting Monday, Signature Bank’s 40 branches will operate under Flagstar Bank, a subsidiary of New York Community Bancorp (ticker: NYCB), the FDIC said Sunday. The FDIC added that all deposits assumed by Flagstar will be insured by the FDIC up to its insurance limit of $250,000.

  • Is it safe to buy now or is this just a 'dead cat bounce'? Morgan Stanley's stock chief says you should sell any rallies — but here are 3 stocks the big bank still likes

    Tough times aren’t over, but opportunities abound.

  • Feeling cold and cash-strapped on the first day of spring? These 4 hot states won't tax your pension income at all — no matter how old you are or how much money you've got

    You earned that money, might as well hold onto it.

  • First Republic stock sinks after credit rating slashed by another three notches at S&P

    First Republic Bank's stock sank toward a record low Monday, after the bank's credit rating was slashed further into junk territory by S&P Global Ratings.

  • Credit Suisse’s $17 Billion of Risky Bonds Are Now Worthless

    (Bloomberg) -- Most Read from BloombergUBS to Buy Credit Suisse in $3.3 Billion Deal to End CrisisCredit Suisse’s $17 Billion of Risky Bonds Are Now WorthlessWarren Buffett in Contact With Biden Team on Banking CrisisCredit Suisse Said to Push Back Against UBS’s $1 Billion OfferFed and Global Central Banks Move to Boost Dollar FundingHolders of Credit Suisse Group AG bonds suffered a historic loss when a takeover by UBS Group AG wiped out about 16 billion Swiss francs ($17.3 billion) worth of ri

  • US Banks on Bumpy Path as First Republic’s Troubles Persist

    (Bloomberg) -- Just weeks ago, they were bit players in the giant US banking system. Now, a handful of regional lenders are at the heart of a crisis that’s shaken the country and engaged the likes of Warren Buffett and Jamie Dimon. Most Read from BloombergUBS to Buy Credit Suisse in $3.3 Billion Deal to End CrisisCredit Suisse’s $17 Billion of Risky Bonds Are Now WorthlessThe One Big Winner and Many Losers of UBS’s Credit Suisse RescueWarren Buffett in Contact With Biden Team on Banking CrisisCr

  • These Stocks Are Moving the Most Today: Credit Suisse, UBS, First Republic, New York Community, and More

    UBS agrees to acquire rival Credit Suisse for more than $3 billion, while shares of First Republic fall sharply after the regional bank’s credit rating was cut again by S&P Global.

  • Credit Suisse Turmoil Puts Gulf Investors Among Biggest Losers

    (Bloomberg) -- Most Read from BloombergUBS to Buy Credit Suisse in $3.3 Billion Deal to End CrisisCredit Suisse’s $17 Billion of Risky Bonds Are Now WorthlessThe One Big Winner and Many Losers of UBS’s Credit Suisse RescueWarren Buffett in Contact With Biden Team on Banking CrisisCredit Suisse Said to Push Back Against UBS’s $1 Billion OfferCredit Suisse Group AG’s Middle Eastern shareholders, which together own about a fifth of the Swiss bank, are among some of the biggest losers in the turmoil

  • Bearish Bets: 3 Stocks You Should Consider Shorting This Week

    Using technical analysis of the charts of those stocks, and, when appropriate, recent actions and grades from TheStreet's Quant Ratings, we zero in on three names. While we will not be weighing in with fundamental analysis, we hope this piece will give investors interested in stocks on the way down a good starting point to do further homework on the names. Estee Lauder Companies Inc. recently was downgraded to Hold with a C+ rating by TheStreet's Quant Ratings.

  • Investors punish UBS after Credit Suisse rescue, shares plummet

    LONDON/ZURICH (Reuters) -Shares in UBS plunged on Monday, heading for their biggest one-day fall since 2008 after its weekend rescue of ailing rival Credit Suisse ignited concerns among investors about the long-term benefits of the deal. UBS, with a hefty backstop from Swiss authorities, agreed to buy Credit Suisse on Sunday for just a fraction of its market value in a package orchestrated by Swiss regulators. The bank will pay 3 billion Swiss francs ($3.23 billion) for Credit Suisse and assume up to $5.4 billion in losses.

  • The One Big Winner and Many Losers of UBS’s Credit Suisse Rescue

    (Bloomberg) -- UBS Group AG is emerging as a rare winner in Credit Suisse Group AG’s crisis after a historic, government-brokered deal that contains a raft of financial shock absorbers. Most Read from BloombergUBS to Buy Credit Suisse in $3.3 Billion Deal to End CrisisCredit Suisse’s $17 Billion of Risky Bonds Are Now WorthlessThe One Big Winner and Many Losers of UBS’s Credit Suisse RescueWarren Buffett in Contact With Biden Team on Banking CrisisCredit Suisse Said to Push Back Against UBS’s $1

  • The banking crisis creates two new questions for investors: Morning Brief

    A fork in the road for investors during all this banking turmoil.

  • HSBC Slumps in Hong Kong as AT1 Debt Selloff Weighs on Banks

    (Bloomberg) -- Shares of European banks traded in Asia tumbled Monday, as investors weighed a collapse in the value of additional tier 1 bonds issued by lenders following the terms of the Credit Suisse Group AG’s rescue.Most Read from BloombergUBS to Buy Credit Suisse in $3.3 Billion Deal to End CrisisCredit Suisse’s $17 Billion of Risky Bonds Are Now WorthlessThe One Big Winner and Many Losers of UBS’s Credit Suisse RescueWarren Buffett in Contact With Biden Team on Banking CrisisCredit Suisse

  • New York Community Bank agrees to purchase failed Signature Bank

    The Federal Deposit Insurance Corporation announced a new deal for the failed Signature Bank to be purchased. The bank collapsed just days after the Silicon Valley Bank.